| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/17/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/17/2023 |
SC 13G/A
| PFM Health Sciences, LP reports a 4.2% stake in Werewolf Therapeutics, Inc. |
| 01/10/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Bought 1,853,000 shares
@ $2.21, valued at
$4.1M
|
|
| 01/10/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 18% stake in Werewolf Therapeutics, Inc. |
| 01/10/2023 |
8-K
| Other Events Interactive Data |
| 01/09/2023 |
4
| HICKLIN DANIEL J (See Remarks) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Granted 295,500 options to buy
@ $2.05, valued at
$605.8k
|
|
| 01/09/2023 |
4
| Lubman Ellen (Chief Business Officer) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Granted 86,200 options to buy
@ $2.05, valued at
$176.7k
|
|
| 01/09/2023 |
4
| Seidel-Dugan Cynthia (Chief Scientific Officer) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Granted 115,900 options to buy
@ $2.05, valued at
$237.6k
|
|
| 01/09/2023 |
4
| Karunatilake Chulani (Chief Technology Officer) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Granted 103,600 options to buy
@ $2.05, valued at
$212.4k
|
|
| 01/09/2023 |
4
| Trost Timothy W. (CFO) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Granted 102,800 options to buy
@ $2.05, valued at
$210.7k
|
|
| 01/09/2023 |
4
| Leonard Reid (COO) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Granted 93,600 options to buy
@ $2.05, valued at
$191.9k
|
|
| 01/09/2023 |
4
| Isaacs Randi (Chief Medical Officer) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Granted 103,300 options to buy
@ $2.05, valued at
$211.8k
|
|
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 09/07/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 08/12/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/07/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/03/2022 |
4
| DiRocco Derek (Director) has filed a Form 4 on Werewolf Therapeutics, Inc.|
Txns:
| Granted 11,600 options to buy
@ $3.43, valued at
$39.8k
|
|
|